Implications of the ATLAS study for clinical practice.
作者信息
Packer M
机构信息
Columbia Presbyterian Medical Center, New York, USA.
出版信息
Int J Clin Pract Suppl. 1999 Apr;100:21-3.
PMID:10658296
Abstract
摘要
相似文献
1
Implications of the ATLAS study for clinical practice.
Int J Clin Pract Suppl. 1999 Apr;100:21-3.
2
Results of the ATLAS study.
Int J Clin Pract Suppl. 1999 Apr;100:17-8.
3
Assessment of Treatment with Lisinopril and Survival ATLAS study.
Int J Clin Pract Suppl. 1999 Apr;100:24.
4
Heart failure management in primary care: implications of the ATLAS study.
Int J Clin Pract Suppl. 1999 Apr;100:25-30.
5
The ATLAS study: low-dose versus high-dose lisinopril in heart failure.
Int J Clin Pract Suppl. 1999 Apr;100:15-6.
6
Causes of death in the ATLAS study: effects of high-dose ACE inhibitors.
Int J Clin Pract Suppl. 1999 Apr;100:19-20.
7
What does ATLAS really tell us about "high" dose angiotensin-converting enzyme inhibition in heart failure?
J Card Fail. 2000 Jun;6(2):165-8.
8
ATLAS: high dose lisinopril is superior to low dose in heart failure.
Int J Clin Pract. 1998 Apr-May;52(3):139.
9
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
Eur Heart J. 2000 Dec;21(23):1967-78. doi: 10.1053/euhj.2000.2311.
10
Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study.
Eur J Heart Fail. 1999 Mar;1(1):73-9. doi: 10.1016/S1388-9842(98)00002-6.
引用本文的文献
1
Pharmacological interventions for heart failure in people with chronic kidney disease.
Cochrane Database Syst Rev. 2020 Feb 27;2(2):CD012466. doi: 10.1002/14651858.CD012466.pub2.
Zotero 插件